|

Nintedanib, gefitinib, erlotinib, afatinib, osimertinib Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • China Medical University Hospital1

Indications

  • EGFR-TKI Resistant Mutation1
  • Lung Cancer1
  • EGFR Gene Mutation1
  • Non Small Cell Lung Cancer1
  • Cancer1

Other1 trial

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.